As Covid occupied the European media landscape over the last two years, the big cannabis debate largely disappeared from the media headlines. But now the attention on Covid is giving way to other issues, the question about whether Europe should legalize cannabis is making a big comeback. Here’s the state of play for the question in Europe and what developments should be expected.
If the subject had disappeared from the jungle of hot European media topics of the last two years, it is now back: the debate on cannabis legalization is picking up again. As the United States continues to implement new reforms at the federal level, it is now only a matter of time before Europe follows suit. Should Europe legalize cannabis, and in particular medical cannabis? Here’s the state of play for the question in Europe and the next developments expected.
But first, take a moment to download our free cannabis news app.
Malta, a European Pioneer
The news fell in early December 2021: Malta becomes the first European country to legalize medical cannabis. This was an unparalleled step forward for the continent, which has been split into two schools for several years on the issue of cannabis, unable to find a single voice for its possible legalization.
Should European countries legalize only medical cannabis, or also recreational? What are the consequences for society and the economy? These are questions that Malta no longer asks itself, having decided to take a step forward in legalization, like many North American and African countries.
Like the Netherlands, Malta is a relatively advanced country on cannabis issues, recognizing the possible benefits of certain substances such as CBD and THC to treat chronic diseases. The country also allows its citizens to possess cannabis for recreational use, in limited quantities, which is a novelty. The question is whether this will pave the way in Europe for other countries, or remain a pioneering example.
France, Still Questioning
According to surveys conducted among the French population, the latter would not be outdone when it comes to cannabis consumption. It even seems that France is one of the countries where the majority of the population has already tested cannabis, unlike many European countries.
In fact, thanks to online resources like cannaconnection , information about cannabis, its risks, and benefits, is always available. And yet, despite this popularity, French cannabis legislation is one of the least advanced in the Western European region.
It may be because France has a difficult history with cannabis, but one thing is certain: things are moving slowly. With the launch of clinical trials in March 2021, France will be one of those European countries that want to have “proof” and concrete facts before making any progress on the legalization of cannabis. Moreover, in France, it is still forbidden to possess, cultivate or consume cannabis, even for personal use.
Germany, a European Ally?
An immediate European neighbor to France could also tip things over at one time or another. Considered as the “driving duo” of Europe, France and Germany are working in synergy and the issue of cannabis could well come back to the fore.
While Germany has shown itself in favor of the legalization of therapeutic, but also recreational cannabis and the liberalization of the European market, it is opening the doors to new economic opportunities, attracting new investors and capital.
It makes for a dynamic in constant development, which calls for even more: the figures concerning the cannabis market by 2050 are absolutely staggering, and many European countries may want, at some point, its share of the cake. Business to follow!
(Featured image by Alesia Kozik via Pexels)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published by Le Petit Journal, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions, or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
J. Frank Sigerson is a business and financial journalist primarily covering crypto, cannabis, crowdfunding, technology, and marketing. He also writes about the movers and shakers in the stock market, especially in biotech, healthcare, mining, and blockchain. In the past, he has shared his thoughts on IT and design, social media, pop culture, food and wine, TV, film, and music. His works have been published in Investing.com, Equities.com, Seeking Alpha, Mogul, Small Cap Network, CNN, Technology.org, among others.